SCOLR Pharma, Inc. Submits Abbreviated New Drug Application For A 12-hour CDT-based Pseudoephedrine Formulation

 23.08.2008 10:17   medicalnewstoday.com

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 89 percent of surveyed rheumatologists anticipate prescribing Roche/Chugai's Actemra, following the expected launch of the drug for rheumatoid arthritis in 2009.

World Arthritis